Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep;18(9):1524-6.
doi: 10.1128/CVI.05207-11. Epub 2011 Jul 27.

Evaluation of the Bio-Rad BioPlex Measles, Mumps, Rubella, and Varicella-Zoster Virus IgG multiplex bead immunoassay

Matthew J Binnicker  1 , Deborah J Jespersen, Leonard O Rollins
Affiliations

Evaluation of the Bio-Rad BioPlex Measles, Mumps, Rubella, and Varicella-Zoster Virus IgG multiplex bead immunoassay

Matthew J Binnicker et al. Clin Vaccine Immunol. 2011 Sep.

Abstract

The goal of this study was to compare the BioPlex 2200 measles, mumps, rubella, and varicella-zoster virus (MMRV) IgG multiplex assays (Bio-Rad Laboratories, Hercules, CA) to routine testing by enzyme immunoassay (EIA). Serum specimens (n = 500) submitted to our reference laboratory for routine MMRV IgG testing by EIA were also tested by the BioPlex assays. Following testing, the BioPlex measles, mumps, rubella, and varicella-zoster virus assays demonstrated agreements of 91.6% (95% confidence interval [CI], 88.8% to 93.7%), 94.2% (95% CI, 91.7% to 95.7%), 94.4% (95% CI, 92.0% to 96.1%), and 91.8% (95% CI, 89.0% to 93.9%), respectively, compared to the results of EIA. Timing studies showed that the BioPlex MMRV assay could provide complete analysis of 100 serum specimens in 1.7 h, compared to 5.5 h by EIA. These data indicate that the BioPlex MMRV IgG assays exhibit comparable performance (93% overall agreement [1,860/2,000 results]; κ = 0.67) to routine testing by EIA. The BioPlex assays allow for the simultaneous detection of all four analytes, thereby eliminating potential aliquot errors and reducing turnaround time.

PubMed Disclaimer

References

    1. Czajka H., et al. 2009. A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile. Vaccine 27:6504–6511 - PubMed
    1. Doshi S., et al. 2009. Ongoing measles and rubella transmission in Georgia, 2004-05: implications for the national and regional elimination efforts. Int. J. Epidemiol. 38:182–191 - PubMed
    1. Kancherla V. S., Hanson I. C. 2006. Mumps resurgence in the United States. J. Allergy Clin. Immunol. 118:938–941 - PubMed
    1. Landis J. R., Koch G. G. 1977. The measurement of observer agreement for categorical data. Biometrics 33:159–174 - PubMed
    1. Mulholland E. K. 2006. Measles in the United States, 2006. N. Engl. J. Med. 355:440–443 - PubMed

Publication types